ApoAII, the second most abundant protein of the human plasma HDLs, was discovered nearly 50 years ago. Over the subsequent years, nearly 2000 studies - epidemiological, cell-based, biochemical, mouse and human - have attempted to unravel its role in human lipid metabolism. On the basis of these studies, apoAII has been described as an activator and inhibitor of various plasma activities, and as both pro- and anti-atherogenic. Here, we summarize the studies of apoAII, use the preponderance of evidence to propose that the apoAII compass can be reset towards an antiatherogenic course, and suggest ways to stay the course.

Original languageEnglish (US)
Pages (from-to)551-560
Number of pages10
JournalClinical Lipidology
Issue number5
StatePublished - Oct 2013


  • atherosclerosis
  • cholesterol
  • epidemiology
  • lipid metabolism
  • lipoprotein therapeutics
  • reverse cholesterol transport

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Setting the course for apoAII: A port in sight?'. Together they form a unique fingerprint.

Cite this